[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361370-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361370-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","outcomes-and-prognostic-factors-in-patients-with-systemic-mastocytosis-and-an-associated-myeloid-neoplasm-an-international-ecnm-registry-study","Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study","","Systemic mastocytosis (SM) is a spectrum of hematologic disorders marked by atypical mast cell accumulation in extracutaneous organs. SM with an associated hematologic neoplasm (SM-AHN) is the most frequent advanced SM subtype and is commonly linked to myeloid neoplasms, requiring robust outcome data for risk stratification. Using the 10th wave ECNM registry, baseline features and overall survival were compared across SM-AHN, SM-no-AHN, and SM components.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/outcomes-and-prognostic-factors-in-patients-with-systemic-mastocytosis-and-an-associated-myeloid-neoplasm-an-international-ecnm-registry-study/361370/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/outcomes-and-prognostic-factors-in-patients-with-systemic-mastocytosis-and-an-associated-myeloid-neoplasm-an-international-ecnm-registry-study/361370.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",18,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)?","Question",{"text":63,"@type":64},"SM-AHN is a subtype of advanced systemic mastocytosis in which systemic mastocytosis co-occurs with an associated hematologic neoplasm, most frequently of myeloid origin.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were outcomes and survival assessed in the study?",{"text":68,"@type":64},"Outcomes and overall survival were analyzed using data from the 10th wave of the ECNM registry, comparing SM-AHN with SM-no-AHN and examining SM-AHN outcomes by mastocytosis component and AHN subtype.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors primarily drive survival in SM-AHN?",{"text":72,"@type":64},"Survival in SM-AHN is driven mainly by the aggressiveness of the mastocytosis component; advanced SM-AHN shows shorter overall survival than non-advanced SM-AHN.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361370,1790216933,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Hermine et al. Journal of Hematology & Oncology (2026) 19:66 [https://doi.org/10.1186/s13045-026-01819-1](https://doi.org/10.1186/s13045-026-01819-1)  \nJournal of Hematology & Oncology  \nRESEARCH Open Access  \nOutcomes and prognostic factors in patients  with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study  \nOlivier Hermine1*, Orianne Debeaupuis1,2, Gandhi Damaj3, Johannes Lübke4, Juliana Schwaab4, Marc Heizmann5, Frank Siebenhaar6,7, Polina Pyatilova6,7, Nicole Nojarov6,7, Marek Niedoszytko8, Aleksandra Gorska8, Mattias Mattsson9, Khalid Shoumariyeh10, Stephan de Bra 10, Friederike Wortmann11, Nikolas von Bubnoff11, Horia Bumbea 12,  \nDelia Soare12, Chiara Elena 13, Judit Várkonyi14, Anna Belloni Fortina 15, Simge Erdem16, Knut Brockow17,  \nTobias Michael Franz 17, Jens Panse18,19, Deborah Christen18,19, Christine Breynaert20, Akif Selim Yavuz21,  \nLuca Malcovati13,22, Michael Doubek23, Vito Sabato24, Ilaria Tanasi25, Massimiliano Bonifacio25, Karin Hartmann26, Axel Rüfer27, Mariarita Sciumè28, Valentina Bellani28, Irena Angelova-Fischer29, Alex Stefan29, Massimo Triggiani30, Roberta Parente30, Saskia K. Klein31, Michael Makris32, Sotirios Papageorgiou32,33, Paul van Daele34, Ingunn Dybedal35, Daniel Baffoe35, Theo Gülen36,37, Madlen Jentzsch38, Olivier Lortholary1, Mael Heiblig39, Cristina Bulai Livideanu40, Stéphane Barete41, Clément Gourguechon42, Sophie Dimicoli-Salazar43, Olivier Tournilhac44, Laurent Frenzel1, Michel Arock45, Andrzej Mital46, Johannes N. Woltsche47, Hanneke C. Kluin-Nelemans48, Joanna N. G. Oude Elberink49, Jason Gotlib50, Martina Sperr51,52, Andreas Reiter4, Peter Valent51,52, Wolfgang R. Sperr51,52 and Julien Rossignol 1*  \nAbstract  \nBackground Systemic mastocytosis (SM) is a spectrum of hematologic disorders characterized by accumulation of atypical mast cells (MCs) in extracutaneous organs. SM with an associated hematologic neoplasm (SM-AHN), the most frequent subtype of advanced SM, is predominantly associated with myeloid neoplasms, consistent with shared clonal architecture. Because of its rarity and heterogeneity, robust outcome data aligned with contemporary classifications are needed to inform risk stratification.  \nMethods We analyzed the 10th data wave of the European Competence Network on Mastocytosis registry (34 European centers and 1 US center) . SM and AHN diagnoses followed the 2022 World Health Organization classification. Baseline characteristics and overall survival (OS) were compared between patients with myeloid  \nSM-AHN and SM without AHN (SM-no-AHN) . Within SM-AHN, outcomes were analyzed by SM component (advanced:  \n*Correspondence: Olivier Hermine [ohermine@gmail.com](ohermine@gmail.com)[ ](ohermine@gmail.com)Julien Rossignol [Julien. rossignol@aphp.fr](Julien. rossignol@aphp.fr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.","cbCaifX18Ri7GSzo","https://ap.wps.com/l/cbCaifX18Ri7GSzo","pdf",1366704,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords","[{\"question\":\"What is systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)?\",\"answer\":\"SM-AHN is a subtype of advanced systemic mastocytosis in which systemic mastocytosis co-occurs with an associated hematologic neoplasm, most frequently of myeloid origin.\"},{\"question\":\"How were outcomes and survival assessed in the study?\",\"answer\":\"Outcomes and overall survival were analyzed using data from the 10th wave of the ECNM registry, comparing SM-AHN with SM-no-AHN and examining SM-AHN outcomes by mastocytosis component and AHN subtype.\"},{\"question\":\"What factors primarily drive survival in SM-AHN?\",\"answer\":\"Survival in SM-AHN is driven mainly by the aggressiveness of the mastocytosis component; advanced SM-AHN shows shorter overall survival than non-advanced SM-AHN.\"}]","Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study | PDF",1790144097,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5895654e7fa2797088d882756eaee40a.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e5d7ad648799af09491e3eb160e1e11.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e924df0bec6d8ddb0ce55d9607dc2ffa.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08a10e88835c9b1cab34531559be49a8.webp",980,1306]